Position in ABVX
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$1,199
New position
Shares Held
9
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#294
of 302 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 78%
Shared 0%
None 22%
Position in Biotechnology
Healthcare · as of Jun 30, 2026FINANCIAL CONSULATE, INC holds $504,194 across 31 Biotechnology names. ABVX ranks #21 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
800 | $195,816 | |
| 2 | ARGX |
Argenx SE
|
107 | $99,271 | |
| 3 | RPRX |
Royalty Pharma plc
|
1,000 | $56,070 | |
| 4 | BNTX |
BioNTech SE
|
370 | $34,428 | |
| 5 | MRNA |
Moderna, Inc.
|
340 | $23,810 | |
| 6 | PCVX |
Vaxcyte, Inc.
|
250 | $14,532 | |
| 7 | CVM |
Cel Sci Corp
|
10,000 | $10,400 | |
| 8 | SLS |
SELLAS Life Sciences Group, Inc.
|
600 | $8,856 |
All Filings in ABVX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,199 | 9 | Shares | Sole | 2026-07-23 | |
| No filing history on record for this holder in this stock. | ||||||